Menu
No results found.
“Patience reduces risk more reliably than prediction.”
Weekly Share Price & Valuation Overview
Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CHF 7.42M
- Enterprise Value Operating value: market cap + total debt − cash.
- CHF 2.90M
- Total Revenue (TTM) Estimated Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CHF 384.89K
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CHF -519.06K
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CHF 0.00
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.05
- Shares Outstanding
- 128.30M
- Float Shares
- 26.11M
- Implied Shares Outstanding
- 128.30M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-8.53%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
-134.86%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
35.22%
- ROA Return on assets: net income ÷ total assets.
-
-25.09%
- ROE Return on equity: net income ÷ shareholder equity.
-
-1.63%
- Revenue Growth Year-over-year revenue growth.
-
-69.80%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 2.71
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.48
- Total Cash Cash and equivalents.
- CHF 2.83M
- Total Debt Short + long-term interest-bearing debt.
- CHF 40.20K
- Net Debt Net Cash Total debt − cash (negative = net cash).
- CHF -2.79M
- Total Revenue (TTM) estimated from Revenue per Share × Shares due to feed inconsistency.
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.